Hemodynamic Alterations in the Coronary Circulation of Cardiomyopathic Hamsters: Age and Ang II-dependent Mechanisms

Journal of Cardiac Failure

Volumn 15, Issue 10, 2009, Pages 929-938

  Escobales, Nelson ^a   Ramos, Jose A ^a   Santacana, Guido E ^a   Crespo, Maria J ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Cardiomyopathic hamsters; coronary hyperreactivity; endothelial dysfunction; nitric oxide; vascular RAS

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCYSTEINE; ANGIOTENSIN II; BRADYKININ; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY VASCULAR RESISTANCE; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL MODEL; HEART DILATATION; HEART HEMODYNAMICS; HEART MUSCLE PERFUSION; HEART MUSCLE RELAXATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AGING; ANGIOTENSIN II; ANIMALS; CARDIOMYOPATHIES; CORONARY CIRCULATION; CRICETINAE; HEART RATE; HEMODYNAMICS; MALE; MESOCRICETUS;

EID: 70450224474     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.06.441     Document Type: Article

References (58)

1. Factor S.M., and Sonnenblick E.H. The pathogenesis of clinical and experimental congestive cardiomyopathies: recent concepts. Prog Cardiovasc Dis 27 (1985) 395-420
2. Forman R., Parmley W.W., and Sonneblick E.H. Myocardial contractility in relation to hypertrophy and failure in myopathic Syrian hamster. J Mol Cell Cardiol 4 (1972) 203-211
3. Gertz E.W. Animal model of human disease: myocardial failure, muscular Dystrophy. Am J Pathol 70 (1973) 151-154
4. Kato Y., Iwase M., Takagi K., Nishizawa T., Kanazawa H., Matsushita A., et al. Differential myolysis of myocardium and skeletal muscle in hamsters with dilated cardiomyopathy: beneficial protective effect of diltiazem. Circ J 70 (2006) 1497-1502
5. Kawada T., Nakatsuru Y., Sakamoto A., Koizumi T., Shin W.S., Okai-Matsuo Y., et al. Strain- and age-dependent loss of sarcoglycan complex in Cardiomyopathic hamster hearts and its re-expression by delta-sarcoglycan gene transfer in vivo. FEBS Lett 458 (1999) 405-408
6. Kawada T., Nakazawa M., Nakauchi S., Yamazaki K., Shimamoto R., Urabe M., et al. Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters. Proc Natl Acad Sci U S A 99 (2002) 901-906
7. Lossnitzer K., Janke J., Hein B., Stauch M., and Fleckenstein A. Disturbed myocardial calcium metabolism: a possible pathogenic factor in the hereditary cardiomyopathy of the Syrian hamster. Recent Adv Stud Cardiac Struct Metab 6 (1975) 207-217
8. Sonnenblick E.H., Fein F., Capasso J.M., and Factor S.M. Microvascular spasm as a cause of cardiomyopathies and the calcium blocking-agent verapamil as potential primary therapy. Am J Cardiol 55 (1985) 179B-184B
9. Strobeck J.E., Factor S.M., Bhan A., Sole M., Liew C.C., Fein F., et al. Hereditary and acquired cardiomyopathies in experimental animals; mechanical, biochemical and structural features. Ann NY Acad Sci 317 (1979) 58-88
10. 2+-release channels during development of heart failure in cardiomyopathic hamsters. Am J Physiol 274 (1998) H1-H7
11. Galle J., Mohr W., Lossnitzer K., and Haferkamp O. Development of necrosis and its sequelae in the myocardium of polymyopathic hamsters (BIO 8262). An electron microscopic study. Virchows Arch B Cell Pathol Incl Mol Pathol 36 (1981) 87-100
12. Factor S.M., and Sonnenblick E.H. Hypothesis: is congestive cardiomyopathy caused by a hyperreactive myocardial microcirculation (microvascular spasm)?. Am J Cardiol 50 (1982) 1149-1152
13. Factor S.M., Minase T., Cho S., Dominitz R., and Sonnenblick E.H. Microvascular spasm in the cardiomyopathic Syrian hamster: a preventable cause of focal myocardial necrosis. Circulation 66 (1982) 342-354
14. Kawano H., and Ogawa H. Endothelial function and coronary spastic angina. Intern Med 44 (2005) 91-99
15. Cohn R.D., Durbeej M., Moore S.A., Coral-Vazquez R., Prouty S., and Campbell K.P. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J Clin Invest 107 (2001) R1-R7
16. Coral-Vazquez R., Cohn R., Moore S.A., Hill J.A., Weiss R.M., Davisson R.L., et al. Disruption of sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98 (1999) 465-474
17. Rouleau J.L., Chuck L.H.S., Hollosi G., Kidd P., Sievers R.E., Wikman-Coffelt J., et al. Verapamil preserves myocardial contractility in the hereditary cardiomyopathy of the hamster. Circ Res 50 (1982) 405-412
18. Wheeler M.T., Allikian M.J., Heydemann A., and McNally E.M. The sarcoglycan complex in striated and vascular smooth muscle. Cold Spring Harb Symp Quant Biol 67 (2002) 389-397
19. Wheeler M.T., Korcarz C.E., Collins K.A., Lapidos K.A., Hack A.A., Lyons M.R., et al. Secondary coronary artery vasospasm promotes cardiomyopathy progression. Am J Pathol 164 (2004) 1063-1071
20. Larsen B.T., Gutterman D.D., Sato A., Toyama K., Campbell W.B., Zeldin D.C., et al. Hydrogen peroxide inhibits cytochrome P450 epoxygenases. Interaction between two endothelium-derived hyperpolarizing factors. Circ Res 102 (2008) 59-67
21. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 75 (1994) 149-155
22. Suzuki S., Ohkusa T., Ono K., Sato T., Yoshida M., Yano M., et al. Beneficial effect of the L- and T-type Ca2+-channel blocker efonidipine on cardiomyopathic hamsters. Circ J 71 (2007) 1970-1976
23. Chen Y.-W., Zhao P., Borup R., and Hoffman E.P. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 151 (2000) 1321-1336
24. McNally E., Allikian M., Wheeler M.T., Mislow J.M., and Heydemann A. Cytoskeletal defects in cardiomyopathy. J Mol Cell Cardiol 35 (2003) 231-241
25. Chang Q., Natelson B.H., Golstein C.D., and Ottenweller J.E. The role of stressor intensity and underlying vasculopathy in altering coronary reactivity in cardiomyopathic hamsters. Psychosom Med 59 (1997) 51-57
26. Conway R.S., Natelson B.H., Chen W.H., and Ting W. Enhanced coronary vasoconstriction in the Syrian myopathic hamster supports the microvascular spasm hypothesis. Cardiovasc Res 28 (1994) 320-324
27. Crespo M.J., Altieri P.I., and Escobales N. Enhanced contractility of Ang II in the aorta of cardiomyopathic hamsters is mediated by an increased Ang II-Binding Capacity And Release of ET-1. Vasc Pharmacol 44 (2006) 247-252
28. Crespo M.J., Escobales N., and Altieri P.I. Altered Vascular function in early stages of heart failure in hamsters. J Card Fail 3 (1997) 311-318
29. Crespo M.J. Vascular alterations during the development and progression of experimental heart failure. J Card Fail 5 (1999) 55-63
30. Conway R.S., Factor S.M., Sonnenblick E.H., and Baez S. Microvascular reactivity of the myopathic Syrian hamster cremaster muscle. Cardiovasc Res 21 (1987) 796-803
31. Chang Q., Natelson B.H., Ottenweller J.E., and Conway R.S. Stress triggers different pathophysiological mechanisms in younger and older cardiomyopathic hamsters. Cardiovasc Res 30 (1995) 985-991
32. Munzel T., Shinning C., Post F., Warnoholtz A., and Schulz E. Pathophysiology, diagnosis, and prognostic implications of endothelial dysfunction. Ann Med 40 (2008) 180-196
33. Escobales N., and Crespo M.J. Angiotensin II-dependent vascular alterations in young cardiomyopathic hamsters: role of oxidative stress. Vasc Pharmacol 44 (2006) 22-28
34. Mollnau H., Oelze M., August M., Wendt M., Daiber A., Schulz E., et al. Mechanisms of increased vascular superoxide production in an experimental model of idiopathic dilated cardiomyopathy. Arterioscler Thromb Vasc Biol 25 (2005) 2554-2559
35. Zhang C., Hein T.W., Wang W., and Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 92 (2003) 322-329
36. Katoh M., Egashira K., Kataoka C., Usui M., Koyanagi M., Kitamoto S., et al. Regression by ACE inhibition of arteriosclerotic changes induced by chronic blockade of NO synthesis in rats. Am J Physiol 280 (2001) H2306-H2312
37. Usui M., Egashira K., Tomita H., Koyanagi M., Katoh M., Shimokawa H., et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 101 (2000) 305-310
38. Fuchs L.C. Superoxide anions contribute to impaired endothelium-dependent relaxation in coronary arteries of young cardiomyopathic hamsters. Endothelium 4 (1996) 141-149
39. Mokuno S., Ito T., Numaguchi Y., Matsui H., Toki Y., Okumura K., and Hayakawa T. Impaired nitric oxide production and enhanced autoregulation of coronary circulation in young spontaneously hypertensive rats at prehypertensive stage. Hypertens Res 24 (2001) 395-401
40. Véronneau M., Tanguay M., Fontaine E., Jasmin G., and Dumont L. Reactivity to endothelium-dependent and -independent vasoactive substances is maintained in coronary resistance vessels of the failing hamster heart. Cardiovasc Res 33 (1997) 623-630
41. Matsuhisa S., Otani H., Okazaki T., Yamashita K., Akita Y., Sato D., et al. N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster. Antioxid Redox Signal 10 (2008) 1999-2008
42. Crespo M.J., Cruz N., Altieri P.I., and Escobales N. Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster. J Cardiovasc Pharmacol Ther 13 (2008) 199-206
43. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97 (1996) 1916-1923
44. Skatchkov M.P., Sperling D., Hink U., Mulsch A., Harrison D.G., Sindermann I., et al. Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. Biochem Biophys Res Commun 254 (1999) 319-324
45. Cruz N., Arocho L., Rosario L., and Crespo M.J. Chronic administration of carvedilol improves cardiac function in 6-month-old Syrian cardiomyopathic hamsters. Pharmacology 80 (2007) 144-150
46. Nishizawa T., Iwase M., Kanazawa H., Ichihara S., Ichihara G., et al. Serial alterations of adrenergic signaling in dilated cardiomyopathic hamsters-possible role of myocardial oxidative stress. Circ J 68 (2004) 1051-1060
47. Bassenge E. Endothelial regulation of coronary tone. In: Ryan U.S., and Rubanyi G.M. (Eds). Endothelial regulation of vascular tone (1992), Marcel Dekker Inc, New York 225-264
48. Gutierrez J.A., Clark S.G., Giulumian A.D., and Fuchs L.C. Superoxide anions contribute to impaired regulation of blood pressure by nitric oxide during the development of cardiomyopathy. J Pharmacol Exp Ther 282 (1997) 1643-1649
49. Ca channels compensate for loss of NO-dependent coronary artery relaxation in cardiomyopathy. Am J Physiol Heart Circ Physiol 279 (2000) H2598-H2603
50. 2 in coronary endothelial dysfunction in transgenic mice with dilated cardiomyopathy. Basic Res Cardiol 103 (2008) 417-430
51. Kataoka C., Egashira K., Inoue S., Takemoto M., Ni W., Koyanagi M., et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39 (2002) 245-250
52. Politano L., Nigro V., Passamano L., Petretta V., Comi L.I., Papparella S., et al. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 11 (2001) 178-185
53. Barresi R., Di Blasi C., Negri T., Brugnoni R., Vitali A., Felisari G., et al. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations. J Med Genet 37 (2000) 102-107
54. Tsubata S., Bowles K.R., Vatta M., Zintz C., Titus J., Muhonen L., et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 106 (2000) 655-662
55. Jefferies J.L., Eidem B.W., Belmont J.W., Craigen W.J., Ware S.M., Fernbach S.D., et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 112 (2005) 655-662
56. Duboc D., Meune C., Lerebours G., Devaux J.Y., Waksmann G., and Becane H.M. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 45 (2005) 855-857
57. Camisi P.G., and Crea F. Coronary microvascular dysfunction. N Engl J Med 356 (2007) 830-840
58. Van de Voorde J., Brochez V., and Vanheel B. Heterogeneous effects of histamine on isolated rat coronary arteries. Eur J Pharmacol 271 (1994) 17-23